MART-1 51–73 peptide

The **MART-1 51–73 peptide** is a 23-amino acid synthetic peptide derived from residues 51 to 73 of the human Melan-A/MART-1 melanoma-associated antigen. It is designed as a class II (HLA-DR4-restricted) helper T-cell epitope vaccine for melanoma immunotherapy. This peptide has been shown to induce the expansion of **CD4+ T helper cells** in HLA-DR4+ melanoma patients, activating both Th1 and Th2 immune responses. In clinical studies, vaccination with this peptide stimulated antigen-specific CD4+ T cells capable of producing IFN-γ and IL-5, recognizing naturally processed MART-1 on tumor cells, and mediating tumor cell lysis via the perforin-granzyme pathway. The peptide binds promiscuously to multiple HLA-DR4 subtypes, suggesting broader patient applicability. Its primary experimental indication is as an **adjuvant cancer vaccine in melanoma**, especially in patients expressing relevant HLA-DR alleles[1][3].

Other names

Melan-A/MART-1 51–73 peptideMART-151-73 peptideMART151-73 peptideMART 151-73 peptide